Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents | November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT...
Fortitude bioresorbable stent

The Fortitude sirolimus-eluting bioresorbable stent.

 

News | Stents Bioresorbable | November 07, 2016
November 7, 2016 — The 28th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 3...
Svelte Medical Systems, CE Mark, Direct RX, Direct sirolimus-eluting coronary stent rapid exchange system, drug-eluting stent, DES
News | Stents | October 28, 2016
October 28, 2016 — Svelte Medical Systems Inc. announced this week it received CE Mark certification of the Direct...
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system

 

Feature | Stents Bioresorbable | October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab | September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) included 11 late-breaking trials and 16 first report...
Absorb, bioresorbable stent, BVS, on OCT

An optical coherence tomography (OCT) image of an Absorb bioresorbable stent. The stent struts are clear, allowing light to pass through, and in some cases magnifying the light that passes through under each strut. Image courtesy of St. Jude Medical.

Blog | Stents Bioresorbable | August 16, 2016
There was an explosion of interest in bioresorbable stents immediately following the July 5, 2016 announcement that the...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
  August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional Cardiology (...
Abbott, Absorb bioresorbable stent, dissolving, UAB, University of Alabama at Birmingham, first in state
News | Stents Bioresorbable | July 26, 2016
July 26, 2016 — On July 20, Massoud Leesar, M.D., of University of Alabama at Birmingham Hospital implanted a patient...
bioresorbable stent, bioabsorbable stent, Absorb BVS, visualizing bioresorbable stents

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system.

Feature | Stents Bioresorbable | July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of...
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable | July 19, 2016
July 19, 2016 — Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with...
Abbott, Absorb bioresorbable stent, University Hospitals Case Medical Center, first Midwest implant
News | Stents Bioresorbable | July 11, 2016
July 11, 2016 — University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, dissolving stent

The Abbott Absorb is the first bioresorbable stent to be cleared for use in the United States. 

Technology | Stents Bioresorbable | July 05, 2016 | Dave Fornell
July 5, 2016 — The U.S. Food and Drug Administration (FDA) has cleared the first fully bioresorbable coronary stent for...
News | Stents Bioresorbable | June 06, 2016
June 6, 2016 — Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable | May 17, 2016
May 17, 2016 — Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016....

Biosensors' Biomatrix stent.

Feature | Stents | May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables...